NCT06625515 2026-02-24First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined CancersAccent TherapeuticsPhase 1 Terminated17 enrolled
NCT03841110 2023-05-01FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsFate TherapeuticsPhase 1 Completed37 enrolled
NCT03538028 2020-10-30A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesIncyte CorporationPhase 1 Completed22 enrolled